AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 3 analysts
Fundamentals
Fundamentals institutional score is 39 using EVA spread proxy -4.0%; growth durability 59.1.
Valuation
Valuation institutional score is 34 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 59 using mean target upside -5.5%; dispersion penalty 9.9; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 40 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is skewing constructive on impact and recency. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. market sentiment provide support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 39.1% above historical median. Valuation is stable — currently in the overvalued zone (z-score: +1.16). Confidence: 75%.
Live forward EPS implies next-12-month EPS of ₹31.46. Applying the stock's normalized valuation corridor produces a fair range of ₹871.44 to ₹1,167.80, with base value near ₹990.68 (+35.7% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹31.46
Forward P/E
23.2x
Base Fair Value
₹990.68
Fair Range
₹871.44 - ₹1,167.80
Upside To Base
+35.7%
Estimate Source
Live forward EPS
Growth Estimate
-42.6%
5Y Average
33.17
Current
43.80
Overvalued
37.12
Undervalued
27.70
5Y Average
13.66
Current
18.04
Overvalued
14.99
Undervalued
11.30
5Y Average
1.94
Current
2.56
Overvalued
2.23
Undervalued
1.65
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -50% vs avg | +22.1% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 48.8x Undervalued | -22% vs avg | -14.9% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -30% vs avg | -25.8% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Undervalued | -38% vs avg | +31.7% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 37.5x Undervalued | -40% vs avg | +29.9% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.4x Premium | +73% vs avg | -6.9% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.0x Undervalued | -55% vs avg | +43.4% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 162.0x Premium | +160% vs avg | -52.7% |
AKUMS DRUGS AND PHARMA L trades at a discount (43.8x vs peer avg 62.2x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., CONCORD BIOTECH LIMITED, BLUE JET HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹392 CrJun 2026Latest net profit
₹45 CrJun 2026Latest EPS
₹2.85Jun 2026Net margin
12.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 316 | 447 | 383 | 298 | 317 | 328 | 337 | 329 | 332 | 309 | 369 | 338 | 392 |
| Expenses + | 503 | 358 | 351 | 359 | 274 | 285 | 303 | 311 | 288 | 292 | 344 | 327 | 344 |
| Operating Profit | -187 | 89 | 32 | -61 | 44 | 43 | 34 | 18 | 44 | 17 | 25 | 12 | 49 |
| OPM % | -59% | 20% | 8% | -20% | 14% | 13% | 10% | 5% | 13% | 5% | 7% | 3.5% | 12% |
| Other Income + | 20 | 4 | 25 | 25 | 26 | 32 | 34 | 32 | 29 | 27 | 26 | 25 | 26 |
| Interest | 4 | 5 | 5 | 5 | 6 | 4 | 2 | 3 | 3 | 2 | 2 | 3 | 2 |
| Depreciation | 7 | 8 | 8 | 9 | 9 | 9 | 11 | 10 | 10 | 11 | 12 | 12 | 13 |
| Profit before tax | -178 | 81 | 43 | -49 | 54 | 62 | 55 | 37 | 60 | 31 | 36 | 22 | 59 |
| Tax % | 6% | 35% | 32% | 18% | 23% | 18% | 25% | 26% | 25% | 25% | 22% | 30% | 24% |
| Net Profit + | -190 | 53 | 29 | -58 | 42 | 50 | 41 | 28 | 45 | 23 | 28 | 15 | 45 |
| EPS in Rs | -13.26 | 3.69 | 2.05 | -4.05 | 2.84 | 3.20 | 2.62 | 1.75 | 2.85 | 1.49 | 1.79 | 0.97 | 2.85 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Un-Audited Financial Results For The Quarter Ended 30Th June, 2026